Agios Pharmaceuticals Q3 Sales $8.96M Miss $9.46M Estimate
Portfolio Pulse from Benzinga Newsdesk
Agios Pharmaceuticals reported Q3 sales of $8.96 million, missing the analyst consensus estimate of $9.46 million by 5.25%. However, this represents a 21.15% increase over the same period last year.
October 31, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Agios Pharmaceuticals reported Q3 sales of $8.96 million, missing the analyst consensus estimate by 5.25%. Despite the miss, sales increased by 21.15% compared to the same period last year.
The miss on sales estimates is likely to have a negative short-term impact on AGIO's stock price as it indicates the company did not meet market expectations. However, the year-over-year growth in sales may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100